KR20100008541A - Composition for promoting the differentiation of human mesenchymal stem cell to adipocytic cells containing the extracts of trichosanthis semen or cannabis semen - Google Patents

Abstract

PURPOSE: A composition promoting adipocyte differentiation of human mesenchymal stem cells is provided to ensure volume and elasticity of the skin and effectively prevent or treat diabetes type 2. CONSTITUTION: A composition for promoting adipocyte differentiation contains Trichosanthis Semen extract or Cannabis Semen extract as an active ingredient. A composition for preventing or treating diabetes contains the Trichosanthis Semen extract or Cannabis Semen extract as an active ingredient. The composition promotes differentiation of human mesenchymal stem cells to adipocytes. The human mesenchymal stem cells are derived from human bone marrow.

Description

Composition for promoting the differentiation of human mesenchymal stem cell to adipocytic cells containing the extracts of Trichosanthis Semen or Cannabis Semen}

The present invention relates to a composition for promoting differentiation of human mesenchymal stem cells into adipocytes, and more particularly, containing human extracts of Gluluin and Mazarin as at least one active ingredient as adipocytes. Promotes differentiation to produce fat cells, imparts volume and elasticity to the skin, promotes adiponectin expression, and contains the extracts of the extract of Joulein or Mazain, which are effective in preventing or treating type 2 diabetes mellitus, and as human mesenchymal stem cells. The present invention relates to a composition for promoting differentiation into adipocytes.

The skin is the largest organ of the human body, occupying about 16% of our body volume, 1.8 m², 2 to 4 mm thick, and weighing about 3 kg. It is the epidermis, dermis and subcutaneous fat layer. Consists of. The skin is in direct contact with the external environment and serves as an important protective barrier to protect the body from various harmful factors such as human harmful microorganisms and external stimuli such as ultraviolet rays, while maintaining the biochemical functions necessary for metabolism of the whole body. Indispensable to the institution. In particular, the subcutaneous fat layer under the dermis is composed of the lobules of adipocytes, which act as a cushion to absorb and protect the organs inside the skin against external heat, and the nutrients of triacylglycerol It can also be stored as an energy source if needed. However, as they age, they are damaged by natural factors and various external stimuli. As a result, skin cells in the skin do not function properly, resulting in skin aging such as wrinkles and loss of elasticity. Done.

In the modern world, especially for women, skin is a major indicator of their health, so skin that loses its elasticity as it ages becomes a sensitive issue for women. In particular, the skin on the face is liable to sag and lose elasticity due to factors such as weight and age. In addition, the decrease in facial elasticity and fat caused by metabolic abnormalities such as hormones, blood, fat, and bone, which occur mainly in postmenopausal women, make women feel a great loss of femininity. Increasing the volume of adipose tissue is a solution to the problems that are very sensitive to women in modern society, and many women try to maintain or increase the firmness of the skin through plastic surgery with side effects and economic burden. do.

Local transplantation surgery is currently widely used to improve the elasticity of the skin. Lipograft surgery is a procedure in which a tulip needle-shaped needle is taken using a syringe having a needle that is not sharp and transplanted to each part of the skin where elasticity is poor. These fat grafts can be applied to fill and improve the wrinkles of aging skin as it ages, to correct the lip, jaw, and forehead lines, skin impregnated by nose shaping and burns or wounds, and areas lost due to cancer resection. The results are showing. However, it has been reported that 40-60% of the graft volume is absorbed back into the body after liposuction (S Eremia et al., Dermatol . Sur. 2000, 26: 1150-1158; Fulton JE et al., Dermatol . Clin 2001, 19 (3): 523-530), fat transplantation of skin is thin subcutaneous fat area is less raised a problem of which the cell mass touched, actually the transplanted fat survival and survival expectancy There is a case in which replanting is not necessary. Therefore, there is an increasing demand for a composition that can sufficiently increase the subcutaneous fat layer while replacing lipostomy with these problems.

Most of the cosmetics that have a skin elasticity promoting effect currently on the market using ingredients having the general efficacy, such as skin wrinkle removal or strengthening the dermis. Decreased skin elasticity is caused by decreased production or destruction of collagen and elastin caused by aging or ultraviolet rays. Various substances have been developed and used for the purpose of suppressing the reduction of collagen and elastin, which causes the decrease in elasticity. Among them, retinoids such as retinol and retinoic acid are typically used. Retinoids have an excellent elasticity-improving effect (Dermatology therapy 1998, 16, 357-364), but they have the disadvantage that irritation occurs even when only a small amount is applied to the skin. Therefore, in recent years, in order to solve the skin irritation problem of these raw materials, there is a demand for the development of cosmetics using natural vegetable raw materials that are safer and have no skin irritation.

Recently, in order to solve the skin irritation problem that occurs in these cosmetic raw materials, there is a demand for the development of cosmetics using natural vegetable raw materials that are safer and have no skin irritation. Since the basic structure of the skin is maintained by the subcutaneous fat tissue, and the subcutaneous fat tissue plays a role in determining the volume and strength of the skin, as described above, it provides elasticity to the dermis or epidermis of the outer skin layer. Increasing the volume of fat tissue may be a better solution for maintaining skin volume.

The basic structure of the skin is maintained by the subcutaneous fat tissue, which acts to determine the volume and strength of the skin. Therefore, as mentioned above, increasing the volume of adipose tissue may be a good solution to maintain the volume and elasticity of the skin rather than the method of imparting elasticity to the dermis or epidermis in the outer skin layer.

Research using fat cells has been actively conducted in various fields. Preadipocytes generally used are widely used cells because they have the property of differentiating into adipocytes by differentiation inducing substances such as insulin. Recently, the mesenchymal stem cell (mesenchymal stem cell) is attracting attention in the study using these fat cells. Mesenchymal stem cells can be differentiated using methods similar to those used to differentiate adipocytes into adipocytes in general (Exp. Cell Res. 2006, 312, 1856-1864). It is widely used in (Science 1999, 284, 143-146). These mesenchymal stem cells are known to be differentiated not only into adipocytes but also into other types of cells such as chondrocytes and bone cells (J. Cell Sci. 2006, 119, 2204-2213), and are distributed in most tissues of the body. It is.

Human mesenchymal stem cells are known to be distributed in most tissues of the body, and adult stem cells are known to be differentiated into adipocytes, chondrocytes, and bone cells (Meirelles et al. , J. Cell Sci . 2006, 119: 2204-2213. Although mesenchymal stem cells vary slightly depending on the tissue of origin, they are generally known to have similar characteristics or characteristics (Sakaguchi et al., Arthritis Rheumat . , 2005. 52: 2521-2529 ). Among them, mesenchymal stem cells derived from human bone marrow have been widely applied to studies on adipocyte differentiation (Pittenger et al., Science 1999, 284: 143-146). The method of differentiating preadipocytes from human subcutaneous tissues into complete adipocytes is known to be insignificant compared to the method of differentiating mesenchymal stem cells into adipocytes. Mesenchymal cells are widely used (Xu et al., Exp. Cell) Res . 2006, 312: 1856-1864.

Diabetes is one of the world's most important adult diseases. Recently, with the rapid economic growth in Korea, the prevalence rate of diabetes reaches 7-8%, and it is a major cause of death in the 60s and 70s. A significant proportion of diabetics suffer from type 2 diabetes. Type 2 diabetes is characterized by insulin secretion and dysfunction and insulin resistance.

Looking at the type 2 diabetes therapeutics known to date, there is a sulfonylurea family of drugs, for example, glibenclamide. These drugs were the first to be used as a diabetic treatment, and showed a therapeutic effect on diabetes by directly acting on the beta cells of the pancreas to promote the secretion of insulin. The big problem with this drug, however, is its efficacy regardless of blood sugar levels, which can lead to hypoglycemia by secreting insulin even when blood sugar is low. This is problematic because hypoglycemia is associated with an increased risk of cardiovascular disease, which is the leading cause of diabetes.

In recent years, thiazolidinedione, a new class of synthetic drugs effective against type 2 diabetes, has also been reported (Nolan et al., N. Engl. J. Med., 331: 1188-1193, 1994). The efficacy of thiazolidinediones as an effective antidiabetic agent is almost consistent with adipogenic action, ie the ability to differentiate from cell and stem cells to adipocytes (Harris and Kletzein, Mol. Pharmacol., 45: 439-445, 1994 Wilson et al., J. Med. Chem., 39: 665-668, 1996). Thiazolidinediones of the reported fat-inducing efficacy have been reported to improve insulin resistance and to normalize the levels of plasma glucose and increased insulin without causing hypoglycemic conditions even at very high doses. However, the main problem of thiazolidinedione is its toxic side effects in vivo, and it is necessary to develop a substance capable of preventing and treating diabetes due to its ability to promote fat differentiation among natural products that are not toxic.

Adiponectin, one of the representative adipokines secreted by adipocytes during adipocyte differentiation, has been reported to exhibit various effects including antidiabetic activity (Clin Nutr. 2004 Oct .; 23 (5)). : 963-74, Adiponectin, the missing link in insulin resistance and obesity). That is, especially in diabetes, adiponectin shows the effect of preventing diabetes by increasing insulin sensitivity and lowering blood sugar. In addition, such adiponectin has been reported as a protein that increases expression as adipocytes differentiate. Thus, substances that increase the expression of adiponectin during adipocyte differentiation may be effective in treating diabetes.

In Korea and in Asia, various medicinal herbs have been used for the treatment of diabetes and various diseases. Herbal medicines that have insulin-sensitive effects that enhance the action of insulin, insulin-like effects that act like insulin, and α-glucoamylase inhibitory effects that interfere with the digestion and absorption of carbohydrates include Yulmu, Baekilpi, Rhubarb root, and Schisandra chinensis. 2005-90867) is known. It has already been found that fractions of Mokdanpi (Korean Patent Publication No. 2005-70704) contain insulin sensitive substances. In particular, the extract of Rhubarb Root showed the effect of lowering blood glucose by increasing glucose utilization in the body by improving insulin sensitivity in 90% of the pancreas from which the pancreas was removed [Choi SB, Park S. 2002. The effects of water extract of Polygonatum Odoratum ( Mill) Druce on insulin resistance in 90% pancreatectomized rats. J Food Sci 67: 2375-2379. Other representatives include Hubac (Korean Patent Publication No. 2004-108500), Ginseng Leaf (Korean Patent Publication No. 2005-71459), and Hwangyeon (Korean Patent Publication No. 2005-89238) have antidiabetic effects. This is known. In addition, several substances are known which increase the expression of adiponectin and exhibit antidiabetic efficacy. Korean Patent Laid-Open Publication No. 2005-95411 discloses a composition for treating type 2 diabetes which increases the concentration of adiponectin in blood by using protein concentrate of Korean crude as an active ingredient, and Korean Patent Laid-Open Publication No. 2005-115874 discloses An adiponectin expression promoter using a nidine compound as an active ingredient is disclosed.

Since fat precursor cells used in diabetes research have the property of differentiating into adipocytes in the presence of an inducer such as insulin, an experiment to investigate the presence of an insulin-like substance (insulin-like substance) that promotes differentiation. Used for In this study, not only preadipocytes but also mesenchymal stem cells are used. In particular, mesenchymal stem cells can be differentiated into adipocytes using a method similar to the method of differentiating adipocytes from subcutaneous tissue into complete adipocytes (Xu et al., The use of small interfering RNAs). to inhibit adipocyte differentiation in human preadipocytes and fetal-femor-derived mesenchymal cells.Exp. Cell Res. 312: 1856-1864, 2006), and is widely used for the study of adipocyte differentiation (Pittenger et al., Multilineage potential of adult human mesenchymal stem cells.Science 284: 143-146, 1999). As such, mesenchymal stem cells that can differentiate into adipocytes are distributed in most tissues of the body. Mesenchymal stem cells have a slight difference in their properties or properties depending on which tissue they are derived from, but are generally known to have similar properties or properties (Sakaguchi et al., Comparison of human stem cells derived from various mesenchymal tissues.Arthritis Rheumat., 52: 2521-2529. 2005).

The Gluan is a seed of the Tricisanthes kirilowii Maxim belonging to the family Cucurbitaceae. The herbaceous plant is a perennial vine, whose leaves and perennial tendrils stick well to other objects and have large bulbs such as sweet potatoes. The leaves are regenerated, divided into 5-7 like maple leaves, with serrates on each lobe. Jalluin's sweetness is sweet, weakness is cold. It is applicable to chest pain, constipation, heart asthma and angina as anti-inflammatory, antitussive and expectorant (Jong-Hee Park, co-author Lee Jung-kyu, Commercial Medicinal Plant Book, p449-p450).

Korean Patent Registration Publication No. 1992-0003620 discloses a composition for preventing and treating diabetes by containing a herbal medicine including a balcuin as an active ingredient.

Mazarine is a Cannabis from Moraceae. Seeds of sativa L.) are dried, whose origin is the annual herb of Central Asia, whose main stem is 1-2.5m in height, grows straight, dull squares, fine hairs and green. The leaves are vivid at the bottom, long lobes, long intestinal bile divided into 5-9, but the upper part is shorted without splitting or splitting into three. Tetrahydrocannabinol, known as hemp, has psychotropic effects, initially with pleasure and hallucinations in the central nervous system and cerebral spinal cord, which pass into paralysis. At the same time, the dense horse comes to the sensory spirits, bringing about the loss of pain, and eventually reaches the communist zone. As soon as it is intestine moisturizes, and combined with passersby, peony, fruit room, rhubarb, bakbak is used to treat constipation. In other words, as soon as the chapter through the stools to come out well. It can be applied to constipation (Park Jong-hee, co-author Lee Jeong-gyu, commercial medicinal plant illustration, p199-p201).

Korean Unexamined Patent Publication No. 2003-0059951 includes a herbal compound containing mazain, that is, an extract consisting of rhubarb, chason, ulriin, betel nut, mazain, earth and sand, dew, pesticide, cornus, fruiting, windproof and poisonous A composition for preventing and treating diabetes is disclosed, and Korean Laid-Open Patent Publication No. 1999-0084271 discloses a tea having a constipation symptom improvement effect including mazain and a method for manufacturing the same, and the Republic of Korea Patent Publication No. 10- 0630410 discloses a topical composition for the prevention and treatment of acne containing the extract of Mazarin. The present invention relates to a composition containing the herbal extract having the ability to inhibit the growth of the ear, synagogues, maine, white oysters and corydalis showing a proliferation inhibitory effect of P. acnes at low concentrations.

Therefore, the present inventors have tried to find a natural product that promotes the differentiation of fat cells that make up the adipose tissue, and when the extracts of gallruin or mazarine to mesenchymal stem cells, the mesenchymal stem cells effectively promote the process of differentiation into adipocytes. At the same time it was found to increase the expression of adiponectin and completed the present invention.

Accordingly, an object of the present invention relates to a composition for promoting differentiation of human mesenchymal stem cells into adipocytes.

In order to achieve the above object, the present invention provides a composition for promoting adipocyte differentiation containing at least one of the parenthesis extract and the mother extract as an active ingredient.

The composition according to the present invention was useful for increasing fat tissue for cosmetic or cosmetic purposes by promoting the differentiation of mesenchymal stem cells into adipocytes by containing at least one active ingredient, such as the parenthesis extract and the mother extract as active ingredients.

The compositions according to the invention also increased adiponectin expression and were useful for the prevention or treatment of type 2 diabetes.

The present invention relates to a composition for promoting adipocyte differentiation, comprising a parenthesis and / or as soon as possible extract as an active ingredient.

As used herein, the term "fat cell differentiation" refers to the differentiation of fat precursor cells or mesenchymal stem cells of an animal, preferably a mammal, into adipocytes, and more preferably human mesenchymal stem cells. Preferably, mesenchymal stem cells derived from human bone marrow differentiate into adipocytes.

In another aspect, the present invention contains the extracts of the parenthesis and / or mzain as an active ingredient to promote differentiation of mesenchymal stem cells (MSC), to form a subcutaneous fat layer or to provide fat cells to the skin volume and elasticity It relates to a cosmetic or cosmetic composition having the effect of imparting.

In another aspect, the present invention relates to a composition for preventing or treating type 2 diabetes by increasing the expression of adiponectin by promoting the differentiation of mesenchymal stem cells by containing the extracts of the parentheses and / or mazarin as an active ingredient.

The parenthesis or motherzain extract used in the present invention can be extracted by a conventional extraction method well known in the art using an organic solvent such as water or mother extract. The parenthesis and mother extract extract promotes the differentiation of adipocytes.

The application site of the cosmetic or cosmetic composition for promoting the differentiation of mesenchymal stem cells according to the present invention includes all the adipose tissue of the body, but is not limited to a specific site, for example, includes a breast region of a woman with a lot of fat layers. can do.

In addition, the fat cell differentiation promoting effect may be effective to increase the prevention and treatment of type 2 diabetes.

The increasing effect of the adipose tissue, but the effect of increasing the adipose tissue for cosmetic or cosmetic purposes, but is not limited thereto. In addition, the fat cell differentiation promoting effect may be an effect of increasing the prevention and treatment of type 2 diabetes.

When the composition according to the present invention is used as a skin external preparation composition, it is not particularly limited in the formulation according to the body part. Specifically, for example, it may be a cosmetic composition having a formulation of a softening lotion, nourishing lotion, massage cream, nutrition cream, pack, gel or skin adhesive type cosmetics, and may also be a lotion, ointment, gel, cream, patch or spray Transdermal dosage forms.

In addition, in the external preparation composition according to each formulation, other ingredients other than the above-mentioned parenthesis or as soon as extract of the present invention can be appropriately selected and blended by those skilled in the art without difficulty according to the formulation or purpose of use of other external preparations. If applied simultaneously with other raw materials, synergistic effects may occur.

In addition, when the composition according to the present invention is used as a pharmaceutical composition, it further contains pharmaceutical supplements and other therapeutically useful substances such as preservatives, stabilizers, hydrating or emulsifying accelerators, salts and / or buffers for controlling osmotic pressure. And may be formulated in various oral or parenteral dosage forms according to conventional methods.

Formulations for oral administration include, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, granules, etc. These formulations may contain diluents (e.g., lactose, dextrose, sucrose, Mannitol, sorbitol, cellulose and glycine) and glidants such as silica, talc, stearic acid and its magnesium or calcium salts and polyethylene glycols. Tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally starch, agar, alginic acid or its sodium salt Pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, and sweeteners. Tablets may be prepared by conventional mixing, granulating or coating methods. Also representative of parenteral formulations are injectable formulations, preferably aqueous isotonic solutions or suspensions.

However, it should be understood that the actual dosage of the active ingredient should be determined in light of several relevant factors such as the severity of the symptom, the route of administration chosen, the subject's age, sex, weight and health condition, and therefore the dosage may be determined in any way. Also, the scope of the present invention is not limited. The daily dosage is 0.1-100mg / kg based on the amount of freeze-dried extract of the parenthesis or the extract according to the present invention, preferably administered once to several times a day.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are only for illustrating the present invention, and the scope of the present invention is not limited thereto.

[ Example  One] Gluluin  Preparation of Extract

30 g of guar luin (pharmaceutical name: Trichosanthis Semen, made in China) was added to 200 ml of ethanol (95.0 to 95.5 v / v%), and then pulverized for 20 minutes at 1500 ° C. at 50 ° C. using an ASE300 ACCELERATED SOLVENT EXTRACOR (DIONEX Corporation) instrument. In addition, using an ultrasonic cleaner (BRANSON Ultrasonics corporation) sonicator device was further ground for 3 days at 50 ℃. The pulverized extract extract was then dried at 40 ° C. for 24 hours using a module spin 40 (Modul spin 40; Biotron corporation) instrument to prepare a sample extract of extract.

[ Example  2] Mazain  Preparation of Extract

As soon as 30 g of Mazarin (Cannabis Semen, Chinese) was extracted in the same manner as in Example 1 to prepare a sample of Mazarine extract.

[ Test Example  1] derived from human bone marrow Mesenchymal stem cells  Efficacy in promoting differentiation into adipocytes

Human bone marrow mesenchymal stem cells (hBM-MSCs) were purchased from Lonza, Inc. Walkersville, MD, USA and cultured according to Ron's instructions. Adipocyte differentiation was achieved using the method recommended by Lonza, except that Troglitazone was used instead of indomethacin to induce adipocyte differentiation of mesenchymal stem cells. Specifically, 1 μg / ml insulin, 1 μM dexamethasone (DEXA) and 0.5 mM isobutyl methyl xanthine (IBMX) were cultured in the culture of mesenchymal stem cells to differentiate stem cells into adipocytes. At the time of inducing adipocyte differentiation, the root extract or the mother extract were added to the medium by 1, 3 and 10 ppm, respectively. As a positive control, 10 mM of glibenclamide and 2 mM of troglitazone (TRO) were used, respectively, and treated with IDX medium. After 14 days of adipocyte differentiation of mesenchymal stem cells, the cell culture medium was removed, the cells were washed with 10 ml of phosphate buffered saline (PBS), and then 0.2 ml / cm 2 of 10% formalin / PBS solution. Cells were fixed for 10 minutes. The fixed cells were washed once with 0.5 ml / cm 2 of 60% isopropanol solution, and lipid bodies were stained for 10 minutes with 0.2 ml / cm 2 staining solution in which Oil Red O was dissolved in 60% isopropanol. Subsequently, restaining with hematoxylin was performed to make cell nuclei easily distinguished, and then observed under a microscope. The results are shown in FIGS. 1 and 2.

As can be seen in the results of Figures 1 and 2, the extracts of the Gluluin and Mazarin according to the present invention promoted the differentiation of adipocytes without inducing cell death of mesenchymal stem cells.

[ Test Example  2] human Mesenchymal stem cells  Quantitative measurement of fat cell differentiation promoting effect

Induced differentiation of adipocytes from mesenchymal stem cells in the same manner as in Test Example 1, divided into seven groups treated only 1μg / ml of insulin in group A (control), 1 μg / ml of insulin in group B, DEXA 1 mM and IBMX 0.5 mM (below IDX) were treated, and group C was further treated with 10 mM of glibenclamide in addition to IDX as a positive control. Groups D, E, and F were treated with 1, 3, and 10 ppm of IDX, and parental or mother extract, respectively. Group G was treated with troglitazone 2 mM in addition to IDX as another positive control. In order to measure the degree of adipocyte differentiation, fat cells were stained with oil red o as in Test Example 1, and the absorbed oil red o was eluted with 100% isopropanol solution and absorbance was measured at 500 nm. 3 and 4 (each data value was corrected with the insulin control).

As can be seen from the results of FIG. 3, when IDX induced differentiation into adipocytes, the adipocyte differentiation of mesenchymal stem cells was 3 and 10 ppm, respectively, compared to the untreated guruin extract. In the treated experimental group, it increased by 23% and 49%. From this result, it was confirmed that administration of 10 ppm of the parenthesis extract dose-dependently promote the adipocyte differentiation of human bone marrow-derived mesenchymal stem cells. This increase was statistically significant, and the statistics were verified by the two-tailed Student's t test, indicating that there was a significant difference when the p value was less than 0.05.

In addition, as can be seen from the results of Figure 4, when the differentiation of adipocytes by IDX, fat cell differentiation of mesenchymal stem cells as soon as 3, 10 ppm as compared to the untreated as soon as extract Phosphorus extract increased by 16% and 42% in the experimental group. From these results, it was confirmed that the treatment of adipocyte differentiation of the bone marrow-derived mesenchymal stem cells promoted dose-dependently in 10 ppm treatment. This increase was statistically significant, and the statistics were verified by the two-tailed Student's t test, indicating that there was a significant difference when the p value was less than 0.05.

[ Test Example  3] human bone marrow Mesenchyme  Stem cell Adiponectin  Expression level measurement

Adiponectin has shown efficacy in preventing diabetes by increasing insulin sensitivity and lowering blood sugar. Therefore, the amount of adiponectin that is a marker of promoting fat differentiation and exhibits antidiabetic efficacy was measured in each cell culture medium.

As in Experiment 2, the differentiation of adipocytes was induced from mesenchymal stem cells, but the experiment was divided into six groups. Group A was treated with only 1 μg / ml insulin (control), group B was treated with insulin 1 μg / ml, DEXA 1 μM and IBMX 0.5 mM (IDX), and group C was a positive control in addition to IDX as glibenclamide. ) 10 μM. Groups D, E, and F were treated with 1, 3, and 10 ppm of IDX, a parenthesis extract, or a mother extract. Troglitazone was excluded from the positive control group because it dramatically increased the amount of adiponectin, and only glibenclamide was used as the positive control group.

In order to measure the expression level of adiponectin, the cell culture medium was taken on day 14 of adipose differentiation, and the amount of adiponectin was quantified using the adiponectin ELISA kit (R & D system, cat.no DY1065) (each data value was insulin And the results are shown in FIGS. 5 and 6.

In the results of Fig. 5, when the differentiation of adipocytes by IDX was induced, the adipocyte differentiation of mesenchymal stem cells was treated with 1, 3, and 10 ppm of the goblet extract of mesenchymal stem cells, respectively. In the experimental group, the expression level of adiponectin was increased by 1.8, 2.0 and 3.8 times. When 10 mM of glibenclamide was treated as a positive control, it increased by 6.0 times. From these results, it was found that the parenthesis extract-containing composition increases the amount of adiponectin, which is a representative marker of adipose differentiation, during adipose differentiation of human bone marrow mesenchymal stem cells. This increase was statistically significant, and the statistics were verified by a two-tailed Student's T test, indicating that there was a significant difference when the p value was less than 0.05.

In addition, in the results of Fig. 6, when the differentiation of adipocytes by IDX was induced, the adipocyte differentiation of mesenchymal stem cells was treated with 1, 3, and 10 ppm of the extracts of mesenchymal stem cells, respectively. In the experimental group, the expression level of adiponectin increased 1.8 times, 2.1 times, and 3.3 times. When 10 mM of glibenclamide was treated as a positive control, it increased by about 10 times. From these results, it was found that as soon as the composition containing the extract extract increases the amount of adiponectin, a representative marker of fat differentiation during the fat differentiation of human bone marrow mesenchymal stem cells. This increase was statistically significant, and the statistics were verified by a two-tailed Student's T test, indicating that there was a significant difference when the p value was less than 0.05.

Examples of preparations for the compositions of the present invention are illustrated below.

Preparation Example 1 Tablet

The tablets were prepared by mixing 100 mg of gall-in or mazain extract according to the present invention, 400 mg of lactose, 400 mg of corn starch, and 2 mg of magnesium stearate, followed by compression according to a conventional method for preparing tablets.

Preparation Example 2 Capsule

Capsules were prepared by mixing 100 mg of gall-in or mazain extracts according to the present invention, 400 mg of lactose, 400 mg of corn starch, and 2 mg of magnesium stearate, and then filling the gelatin capsules according to a conventional method for preparing capsules.

Figure 1 is a micrograph of the mesenchymal stem cells after treatment with the extract.

Figure 2 is a micrograph observing mesenchymal stem cells after the treatment as soon as extract.

Figure 3 is a graph showing the results of promoting the adipocyte differentiation by the extract.

Figure 4 is a graph showing the results of promoting adipocyte differentiation by extracts as soon as possible.

Figure 5 is a graph showing the increase in adiponectin expression by the parenthesis extract.

Figure 6 is a graph showing the increase in adiponectin expression by the extract as soon as possible.

Claims (6)

A composition for promoting adipocyte differentiation comprising at least one of a parenthesis extract and a mother extract as an active ingredient. A composition for preventing or treating diabetes, which promotes adiponectin expression by containing at least one of a parenthesis extract and a mother extract as an active ingredient. The composition of claim 1 or 2, wherein the composition promotes differentiation of mesenchymal stem cells into adipocytes. The composition of claim 1 or 2, wherein the composition increases adipose tissue. The composition of claim 3, wherein the mesenchymal stem cells are human mesenchymal stem cells. 6. The composition of claim 5, wherein the mesenchymal stem cells of human are mesenchymal stem cells derived from human bone marrow.

Images